Drug intelligence / Profile preview

Senomega

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Senomega is a health functional food (dietary supplement) developed and marketed by Daewoong Pharmaceutical in South Korea. It is primarily formulated to support cardiovascular health and improve blood circulation. The product typically contains omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are known to help reduce serum triglyceride levels and inhibit platelet aggregation. It is part of Daewoong's portfolio targeting aging-associated symptoms and general wellness, and is distributed through various offline and online channels in the South Korean market.

Brand names: Senomega
Other names: 세노메가

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on Senomega.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senomega.

Explore the full profile